IBDEI17E ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19553,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right dominant side
 ;;^UTILITY(U,$J,358.3,19553,1,4,0)
 ;;=4^I69.151
 ;;^UTILITY(U,$J,358.3,19553,2)
 ;;=^5007441
 ;;^UTILITY(U,$J,358.3,19554,0)
 ;;=I69.152^^67^877^39
 ;;^UTILITY(U,$J,358.3,19554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19554,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left dominant side
 ;;^UTILITY(U,$J,358.3,19554,1,4,0)
 ;;=4^I69.152
 ;;^UTILITY(U,$J,358.3,19554,2)
 ;;=^5007442
 ;;^UTILITY(U,$J,358.3,19555,0)
 ;;=I69.153^^67^877^42
 ;;^UTILITY(U,$J,358.3,19555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19555,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff right nondom side
 ;;^UTILITY(U,$J,358.3,19555,1,4,0)
 ;;=4^I69.153
 ;;^UTILITY(U,$J,358.3,19555,2)
 ;;=^5007443
 ;;^UTILITY(U,$J,358.3,19556,0)
 ;;=I69.154^^67^877^40
 ;;^UTILITY(U,$J,358.3,19556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19556,1,3,0)
 ;;=3^Hemiplga fol ntrm intcrbl hemor aff left nondom side
 ;;^UTILITY(U,$J,358.3,19556,1,4,0)
 ;;=4^I69.154
 ;;^UTILITY(U,$J,358.3,19556,2)
 ;;=^5007444
 ;;^UTILITY(U,$J,358.3,19557,0)
 ;;=I69.851^^67^877^47
 ;;^UTILITY(U,$J,358.3,19557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19557,1,3,0)
 ;;=3^Hemiplga fol oth cerebvasc disease aff right dominant side
 ;;^UTILITY(U,$J,358.3,19557,1,4,0)
 ;;=4^I69.851
 ;;^UTILITY(U,$J,358.3,19557,2)
 ;;=^5007535
 ;;^UTILITY(U,$J,358.3,19558,0)
 ;;=I69.852^^67^877^48
 ;;^UTILITY(U,$J,358.3,19558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19558,1,3,0)
 ;;=3^Hemiplga fol oth cerebvasc disease aff left dominant side
 ;;^UTILITY(U,$J,358.3,19558,1,4,0)
 ;;=4^I69.852
 ;;^UTILITY(U,$J,358.3,19558,2)
 ;;=^5007536
 ;;^UTILITY(U,$J,358.3,19559,0)
 ;;=I69.853^^67^877^49
 ;;^UTILITY(U,$J,358.3,19559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19559,1,3,0)
 ;;=3^Hemiplga fol oth cerebvasc disease aff right nondom side
 ;;^UTILITY(U,$J,358.3,19559,1,4,0)
 ;;=4^I69.853
 ;;^UTILITY(U,$J,358.3,19559,2)
 ;;=^5007537
 ;;^UTILITY(U,$J,358.3,19560,0)
 ;;=I69.854^^67^877^50
 ;;^UTILITY(U,$J,358.3,19560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19560,1,3,0)
 ;;=3^Hemiplga fol oth cerebvasc disease aff left nondom side
 ;;^UTILITY(U,$J,358.3,19560,1,4,0)
 ;;=4^I69.854
 ;;^UTILITY(U,$J,358.3,19560,2)
 ;;=^5007538
 ;;^UTILITY(U,$J,358.3,19561,0)
 ;;=I69.251^^67^877^51
 ;;^UTILITY(U,$J,358.3,19561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19561,1,3,0)
 ;;=3^Hemiplga fol oth ntrm intcrn hemor aff right dominant side
 ;;^UTILITY(U,$J,358.3,19561,1,4,0)
 ;;=4^I69.251
 ;;^UTILITY(U,$J,358.3,19561,2)
 ;;=^5007473
 ;;^UTILITY(U,$J,358.3,19562,0)
 ;;=I69.252^^67^877^52
 ;;^UTILITY(U,$J,358.3,19562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19562,1,3,0)
 ;;=3^Hemiplga fol oth ntrm intcrn hemor aff left dominant side
 ;;^UTILITY(U,$J,358.3,19562,1,4,0)
 ;;=4^I69.252
 ;;^UTILITY(U,$J,358.3,19562,2)
 ;;=^5007474
 ;;^UTILITY(U,$J,358.3,19563,0)
 ;;=I69.253^^67^877^53
 ;;^UTILITY(U,$J,358.3,19563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19563,1,3,0)
 ;;=3^Hemiplga fol oth ntrm intcrn hemor aff right nondom side
 ;;^UTILITY(U,$J,358.3,19563,1,4,0)
 ;;=4^I69.253
 ;;^UTILITY(U,$J,358.3,19563,2)
 ;;=^5007475
 ;;^UTILITY(U,$J,358.3,19564,0)
 ;;=I69.254^^67^877^54
 ;;^UTILITY(U,$J,358.3,19564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19564,1,3,0)
 ;;=3^Hemiplga fol oth ntrm intcrn hemor aff left nondom side
